AR015310A1 - Nuevas drogas del canal de potasio y sus usos - Google Patents

Nuevas drogas del canal de potasio y sus usos

Info

Publication number
AR015310A1
AR015310A1 ARP990102703A ARP990102703A AR015310A1 AR 015310 A1 AR015310 A1 AR 015310A1 AR P990102703 A ARP990102703 A AR P990102703A AR P990102703 A ARP990102703 A AR P990102703A AR 015310 A1 AR015310 A1 AR 015310A1
Authority
AR
Argentina
Prior art keywords
channels
compounds
binders
relates
present
Prior art date
Application number
ARP990102703A
Other languages
English (en)
Original Assignee
Advanced Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc filed Critical Advanced Medicine Inc
Publication of AR015310A1 publication Critical patent/AR015310A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invencion se relaciona con nuevos compuestos multienlazantes que se enlazan a los canales de potasio (K+) y modulan su actividad. Loscompuestos de esta invencion comprenden ligantes de los canales 2-10 K+, covalentemente conectados por un enlazante o enlazantes, donde los ligantes ensu estado monovalente (p.e., no ligados) se enlazan y son capaces de modular la actividad de uno o más tipos de canales K+. La manera de enlazarse los ligantesen conjunto es tal que los agentesmultienlazantes así formados demuestran un efecto biologico y/o terapéutico incrementado, al ser comparado con el mismonumero de ligantes no enlazados puestos a disposicion por el enlace al canal K+. La invencion también se relaciona a los métodos de uso de tales compuestosy a los métodos de preparacion. Los compuestos de esta invencion son particularmente utiles en el tratamiento de enfermedades y condiciones demamíferos que son mediadas por los canales K+. Por consiguiente, lapresente invencion se relaciona también a composiciones farmacéuticas que comprenden unexcipiente aceptable farmacéuticamente y a una cantidad efectiva del compuesto de la presente invencion.
ARP990102703A 1998-06-08 1999-06-08 Nuevas drogas del canal de potasio y sus usos AR015310A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8846598P 1998-06-08 1998-06-08
US9306898P 1998-07-16 1998-07-16
US11386498P 1998-12-24 1998-12-24

Publications (1)

Publication Number Publication Date
AR015310A1 true AR015310A1 (es) 2001-04-18

Family

ID=27375970

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102703A AR015310A1 (es) 1998-06-08 1999-06-08 Nuevas drogas del canal de potasio y sus usos

Country Status (7)

Country Link
EP (1) EP1086063A4 (es)
JP (1) JP2002517466A (es)
AR (1) AR015310A1 (es)
AU (1) AU4426499A (es)
CA (1) CA2318745A1 (es)
SG (1) SG80037A1 (es)
WO (1) WO1999064050A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019067C1 (de) * 2000-04-18 2001-10-04 Lohmann Therapie Syst Lts Transdermales Therapeutisches System zur Abgabe von Dofetilid und seine Verwendung
SI1345595T1 (sl) * 2000-09-29 2007-08-31 Solvay Pharm Bv Farmacevtska oblika s podaljĺ anim sproĺ äśanjem, ki je neodvisna od ionske jakosti
JP2005506039A (ja) * 2000-12-29 2005-03-03 ネオジェネシス ファーマシューティカルズ インコーポレイテッド アフィニティ選択に基づいた疎水性タンパク質のスクリーニング
US9782488B2 (en) 2007-03-12 2017-10-10 Nektar Therapeutics Oligomer-beta blocker conjugates
KR20100135909A (ko) 2008-04-17 2010-12-27 사노피-아벤티스 심혈관성 입원 또는 사망을 예방하는데 사용하기 위한 약제의 제조에 있어서의 드로네다론의 용도
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126124T2 (de) * 1990-09-28 1997-08-28 Neorx Corp Polymere träger zur freisetzung kovalent gebundener wirkstoffe
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support

Also Published As

Publication number Publication date
WO1999064050A1 (en) 1999-12-16
EP1086063A1 (en) 2001-03-28
JP2002517466A (ja) 2002-06-18
EP1086063A4 (en) 2001-03-28
CA2318745A1 (en) 1999-12-16
SG80037A1 (en) 2001-04-17
WO1999064050A8 (en) 2000-02-24
WO1999064050A9 (en) 2000-04-20
AU4426499A (en) 1999-12-30

Similar Documents

Publication Publication Date Title
CR9879A (es) Moduladores de ccr5 (divisional de la solicitud n° 6392)
DE69737867D1 (de) Zielgerichtete kombinations-immuntherapie für krebs
NO20026255L (no) Polymere micellesammensetninger
DK1242401T3 (da) Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf
BR9905977A (pt) Moduladores de ccr5
TR200001840T2 (tr) Arile bağlı azopolisiklik bileşikler
ECSP056256A (es) Moduladores delta-opioides triciclicos
ES2168737T3 (es) Inhibidores de la oxido nitrico sintasa.
AR010752A1 (es) COMPUESTOS QUE SE ENLAZAN A Y ACTIVAN UN RECEPTOR DE LA TROMBOPOYETINA; COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, SU USO PARA LA PREPARACION DE MEDICAMENTOS, Y PROCESO PARA PREPARAR DICHA COMPOSICIoN.
HN1999000080A (es) Derivados de isotiazol utiles como agentes anticancerosos.
DE60031793D1 (de) Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
BR0010700A (pt) Conjugados análogos de poliamina e conjugados de quinona como terapias para cânceres e doenças na próstata
PA8582701A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
ES2165723T3 (es) Composiciones farmaceuticas conteniendo mupirocina.
GT199800106A (es) Azetidinas.
ECSP077230A (es) Moduladores delta-opioides triciclicos
AR015310A1 (es) Nuevas drogas del canal de potasio y sus usos
PT1105114E (pt) Composicoes farmaceuticas topicas contendo nimesulide
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
UY26877A1 (es) Compuestos pirazol-tiazol, composiciones farmacéuticas que los contienen, y su modo de empleo para inhibir quinasas ciclino- dependientes
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
ECSP993000A (es) Nuevas drogas del canal de potasio y sus usos
ATE331730T1 (de) Neue depsipeptid-verbindung
ES2161913T3 (es) Complejos cationicos trinucleares de platino que tienen una actividad antitumoral y composiciones farmaceuticas que los contienen.